Pimicotinib

Pimicotinib (ABSK021) is a selective and orally active CSF1R inhibitor with an IC50 value of 19.48 nM (determined by inhibiting ADP production) . Pimicotinib exhibits anti-tumor activity[1][2][3].

Product Specifications

CAS Number

[2253123-16-7]

Product Name Alternative

ABSK021

UNSPSC

12352005

Target

C-Fms; c-Kit; PDGFR

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/pimicotinib.html

Purity

99.92

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(N1C(C(C)(CC1)C)=O)NC2=CC=C(OC3=CC=NC(C4=CN(C)N=C4)=C3)C(C)=N2

Molecular Formula

C22H24N6O3

Molecular Weight

420.46

References & Citations

[1]Zhao BW, et al. N- (azaaryl) cyclolactam-1-carboxamide derivative, preparation method and application. World Intellectual Property Organization, WO2018214867 A1. 2018-11-29.|[2]Zhang N, et al. Abstract LB077: CSF-1R inhibition with Pimicotinib (ABSK021) enhanced anti-tumor efficacy of KRASG12C inhibitors in preclinical non-small cell lung cancer mouse models. Cancer Research, 2024, 84 (7_Supplement) : LB077-LB077.|[3]Yang S, et al. Abstract LB-288: A highly selective small molecule CSF-1R inhibitor demonstrates strong immunomodulatory activity in syngeneic models. Cancer Research, 2018, 78 (13_Supplement) : LB-288-LB-288.